03525510 News Today

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Anika Therapeutics to post earnings of ($0.19) per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call […]

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) and T2 Biosystems (NASDAQ:TTOO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation. Analyst Recommendations This is a summary of […]

Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 523,000 shares, a growth of 6.9% from the November 15th total of 489,100 shares. Based on an average daily trading volume, of 179,700 shares, the days-to-cover […]

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Volatility and Risk Anika Therapeutics has a beta of […]

Ziegler Capital Management LLC grew its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) by 52.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,593 shares of the biotechnology company’s stock after buying an additional 9,860 shares during the quarter. […]

StockNews.com assumed coverage on shares of Anika Therapeutics (NASDAQ:ANIK – Free Report) in a report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on ANIK. Barrington Research upgraded Anika Therapeutics from a market perform rating to an […]

StockNews.com started coverage on shares of Anika Therapeutics (NASDAQ:ANIK – Free Report) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock. Several other research analysts also recently weighed in on ANIK. Stephens dropped their target price on shares of Anika Therapeutics from $28.00 to […]

Yousif Capital Management LLC trimmed its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) by 7.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,330 shares of the biotechnology company’s stock after selling 690 shares during the period. Yousif Capital Management […]

Anika Therapeutics (NASDAQ:ANIK – Free Report) and Regenicin (OTCMKTS:RGIN – Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 88.3% of Anika Therapeutics shares are […]

Prio Wealth Limited Partnership bought a new position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,800 shares of the biotechnology company’s stock, valued at approximately $852,000. Prio Wealth […]